<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04566211</url>
  </required_header>
  <id_info>
    <org_study_id>VGHKS19-CT6-15</org_study_id>
    <nct_id>NCT04566211</nct_id>
  </id_info>
  <brief_title>Comparing the Efficacy of 10-day Reverse Hybrid Therapy and 10-day Triple Therapy Plus Bismuth Therapy.</brief_title>
  <official_title>Comparing 10-day Reverse Hybrid Therapy and 10-day Triple Therapy Plus Bismuth Therapy on Helicobacter Pylori Eradication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Veterans General Hospital.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reverse hybrid therapy achieves a higher eradication rate than triple therapy plus bismuth&#xD;
      therapy remains unanswered.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the rising prevalence of antimicrobial resistance, the failure rate of the 7-day&#xD;
      standard triple therapy has declined to unacceptable level (&lt;80%) worldwide. Several regimens&#xD;
      were suggested to replace standard triple therapy in the area with high clarithromycin&#xD;
      resistance, including sequential therapy, concomitant therapy, hybrid therapy and bismuth&#xD;
      containing quadruple therapy. A 14-day hybrid therapy invented by our study group appears&#xD;
      very promising in H. pylori eradication, achieving eradication rates of 95%. A clinical trial&#xD;
      by Hsu et al from our hospital showed 12-day reverse hybrid therapy also achieved high&#xD;
      eradication rate, and improved the compliance of patients. Even prolong the treatment&#xD;
      duration of standard triple therapy from 7 days to 12 days, the efficacy of eradication was&#xD;
      still &lt; 90% (85-88%). The limitation of triple therapy in against resistant-stains was still&#xD;
      existed. The addition of bismuth (triple therapy plus bismuth) can improve cure rates despite&#xD;
      a high prevalence of antimicrobial resistance. The major bismuth effect is to add an&#xD;
      additional 30%-40% to the success with resistant infections. However the direct compare the&#xD;
      efficacy between 10-day reverse hybrid therapy and 10-day triple therapy plus bismuth is&#xD;
      still insufficiency in Taiwan and worldwide. Choosing a navel therapy or a modifying triple&#xD;
      therapy can get better efficacy, it is remained to be determined. Besides genotyping&#xD;
      polymorphism of CYP2C19 influenced the metabolism of proton pump inhibit, and could cause&#xD;
      decreasing of eradication rate of standard triple therapy. But the influence in 10-day&#xD;
      reverse hybrid therapy and 10-day triple therapy plus bismuth is unclear.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants in Which H. Pylori Was Eradicated</measure>
    <time_frame>sixth week after the end of anti- H. pylori therapy</time_frame>
    <description>To assess eradication efficacy,repeated endoscopy with rapid urease test, histological examination and culture or Urea breath test.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>(panto+amox+clar+metr)+(panto+amox)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 3-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pantoprazole+bismuth+amox+clar</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pantoprazole 40 mg twice daily, bismuth subcitrate 240 mg twice daily, and amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(panto+amox+clar+metr)+(panto+amox)</intervention_name>
    <description>a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 3-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily</description>
    <arm_group_label>(panto+amox+clar+metr)+(panto+amox)</arm_group_label>
    <other_name>pantoprazole 40 mg</other_name>
    <other_name>amoxicillin 1 g</other_name>
    <other_name>clarithromycin 500 mg</other_name>
    <other_name>metronidazole 500 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pantoprazole+bismuth+amox+clar</intervention_name>
    <description>pantoprazole 40 mg twice daily, bismuth subcitrate 240 mg twice daily, and amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days</description>
    <arm_group_label>pantoprazole+bismuth+amox+clar</arm_group_label>
    <other_name>pantoprazole 40 mg</other_name>
    <other_name>bismuth subcitrate 120 mg</other_name>
    <other_name>amoxicillin 1 g</other_name>
    <other_name>clarithromycin 500 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consecutive H pylori-infected outpatients, at least 20 years of age, with&#xD;
             endoscopically proven peptic ulcer diseases or gastritis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous H pylori-eradication therapy&#xD;
&#xD;
          -  ingestion of antibiotics or bismuth within the prior 4 weeks&#xD;
&#xD;
          -  patients with allergic history to the medications used&#xD;
&#xD;
          -  patients with previous gastric surgery&#xD;
&#xD;
          -  the coexistence of serious concomitant illness (for example, decompensated liver&#xD;
             cirrhosis, uremia)&#xD;
&#xD;
          -  pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feng-Woei Tsay, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Veterans General Hospital.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng-Woei Tsay, Bachelor</last_name>
    <phone>+886-7-342-2121</phone>
    <phone_ext>72075</phone_ext>
    <email>fwchaie@vghks.gov.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng-Woei Tsay, Bachelor</last_name>
      <phone>886-7346-8233</phone>
      <email>fwchaie@vghks.gov.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Veterans General Hospital.</investigator_affiliation>
    <investigator_full_name>Feng-Woei Tsay</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Eradication rate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Bismuth tripotassium dicitrate</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

